Hai is withdrawing its application for listing of 1.8 billion injection strains 3 million instant waterdrifts

Pharmaceutical Network July 2nd, June 30, Haizheng Pharmaceutical signed a notice that it received the State Drug Administration on the company's initiative to apply for the withdrawal of the application for registration of hydrochloric acid Yiliitikang injection drug "approval notice", the company on May 9, 2012 according to the original medicine 6 categories to the Zhejiang Provincial Drug Administration to submit a registration application and received acceptance, up to now the company has invested in the product research and development project of about 301.17 million yuanTable 1:basic information on drugSource: Company Announcement
Notice mentioned in the announcement that Haizheng Pharmaceutical co.,classified 6 categories of the original chemicaldrugs on May 9, 2012, submitted to the Zhejiang Provincial Drug Administration the application for registration of ilithikang injection drugs hydrochloric acid and received acceptanceBased on the current production conditions and market competition assessment, combined with the actual situation of the company, after careful study decided to the State Drug Administration to voluntarily withdraw the drug registration applicationUp to now, the company has invested about 301.17 million yuan in research and development projectsHaizheng Pharmaceuticals said that the company's application to withdraw the registration application of the hydrochloric acid Ilithikang injection will not have a significant impact on the company's current performanceFigure 1: Ilithikang's sales (units: 10,000 yuan)Source: Minnet China's public medical institutions terminal competition pattern
Figure 2: Domestic listed Yilithikang-related productsSource: Minnet one-click searchIlithikang injections for patients with advanced colorectal cancer treatment, Minet data show that 2019 Annual sales of Yilithikang, of China's public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions), have been listed, including products that are listed, ilikitkang injections, injections with Ilitikang, of which the competitive of ilikitkang injections of hydrochloric acid has 6 enterprises 　　Hydrochloric acid Ilitikon injection liquid research drug developed by Pfizer, in China's public medical institutions terminal market share in 2019 only 17.53%; 　　Source: Minnet database, company announcement
review data statistics as of July 1, 2020, if there are any errors, please point out